Kiadis Pharma Announces Enrollment of First Patients in a Multinational Registration Study for ATIR(TM)
Pharma announces today that the first patients have been enrolled in its
multinational registration clinical trial with ATIR(TM). The study is
designed to show reduction in transplant related mortality (TRM) after one
year following an allogeneic stem cell transplantation with a mismatched
(haplo-identical) donor in blood cancer patients eligible for an allogeneic
stem cell transplantation but without having a matched donor available.
The study is currently open for enrollment in centers in
“We are very pleased to initiate the registration study following
excellent clinical results from the phase I/II study with ATIR(TM).” says Dr.
post transplantation and a high overall survival in a patient population with
no standard treatment options left. As an orphan product addressing a high
unmet need, we aim to take advantage of a fast development path for ATIR(TM).”
“As the pioneer of ATIR(TM) I am very excited about this next major
development milestone, a multinational registration study” says Dr.
Claude Roy
ATIR(TM) will open up a whole new treatment field for a very large patient
group which currently has no treatment options left.”
About ATIR(TM)
ATIR(TM), a donor lymphocyte preparation depleted of alloreactive
T-cells, is under development to reduce transplant related mortality (TRM)
following an allogeneic hematopoietic stem cell transplantation (HSCT).
ATIR(TM) is designed to provide early immune reconstitution to fight
infections and remaining tumor cells (by eliminating the use of prophylactic
immune suppressants) while preventing acute severe (Grade III/IV) Graft
versus Host Disease. ATIR(TM) thereby significantly improves the outcome of
the transplant procedure. Moreover, it enables the use of a mismatched,
related (haplo-identical) donor, thus providing virtually everyone with an
immediately available donor and treatment, thereby addressing a high unmet
medical need as patients eligible for an allogeneic transplantation but
without a matched donor available in general have no treatment options left.
ATIR(TM) has been granted orphan drug designations from both the FDA and
the EMEA.
About Kiadis Pharma
Kiadis Pharma is an oncology focused biopharmaceutical development
company with cell based products in clinical development. The company
develops products that offer novel treatment options for terminally ill
cancer patients and address significant unmet medical needs. The key focus
indication for Kiadis Pharma is limitations and complications of bone marrow
transplantation procedures. Kiadis Pharma is located in
Netherlands
http://www.kiadis.com.
English release is provided by Kiadis Pharma. Equivalent translations are
from a third party.
SOURCE Kiadis Pharma